PCDHB2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

Target Name: PCDHB2

NCBI ID: G56133

PCDHB2

PCDHB2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

PCDHB2 (Protocadherin beta-2) is a protein that is expressed in various tissues throughout the body, including the placenta, brain, and heart. It is a member of the protocadherin family, which is a group of transmembrane proteins that play a crucial role in cell-cell adhesion. PCDHB2 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

PCDHB2 function and structure

PCDHB2 is a 21-kDa protein that consists of 154 amino acid residues. It has a unique structure that is composed of a long extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain of PCDHB2 consists of a N-terminus that is responsible for interacting with cell surface receptors, a transmembrane region that spans the entire length of the protein, and a C-terminus that is involved in cell adhesion.

The transmembrane region of PCDHB2 is characterized by the presence of a unique heparan sulfate proteoglycan (HSPG) domain. This domain is known for its ability to interact with various signaling molecules, including tyrosine and estrogen. The HSPG domain is also involved in modulating the activity of PCDHB2, which may play a role in its therapeutic potential.

The intracellular domain of PCDHB2 is characterized by the presence of a unique nucleotide-binding oligomerization domain (NBO) that is involved in the regulation of gene expression. This domain is known for its ability to interact with various nuclear proteins, including transcription factors.

Expression and function

PCDHB2 is expressed in a variety of tissues throughout the body, including the placenta, brain, and heart. It is highly expressed in the placenta, where it is involved in the development and maintenance of the neural tube. PCDHB2 is also expressed in the brain , where it is involved in the regulation of neural cell adhesion and the development of neurodegenerative diseases.

PCDHB2 is involved in cell-cell adhesion by modulating the activity of various signaling pathways. For example, it has been shown to play a role in the regulation of T cell development and activation. PCDHB2 has also been shown to play a role in the regulation of cancer cell growth and metastasis.

PCDHB2 has also been shown to be involved in the regulation of stem cell proliferation and differentiation. For example, PCDHB2 has been shown to play a role in the regulation of the self-renewal ability of stem cells.

PCDHB2 as a drug target

PCDHB2 has been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The PCDHB2 protein is currently being targeted by a number of research studies, including those aimed at developing new treatments for cancer, neurodegenerative diseases, and developmental disorders.

One approach to targeting PCDHB2 is to use small molecules that can modulate its activity. For example, researchers have shown that inhibitors of the HSPG domain of PCDHB2 can effectively inhibit the activity of PCDHB2, including its ability to regulate cell adhesion. Similarly, inhibitors of the NBO domain of PCDHB2 have also been shown to be effective in inhibiting the activity of PCDHB2.

Another approach to targeting PCDHB2 is to use antibodies that can specifically recognize and target the PCDHB2 protein. For example, researchers have shown that antibodies specific for the PCDHB2 protein can effectively block its activity

Protein Name: Protocadherin Beta 2

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets